Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
2000 1
2004 2
2010 3
2011 2
2012 3
2014 3
2016 1
2017 3
2018 6
2019 2
2020 5
2021 3
2022 4
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Crestani B, Huggins JT, Kaye M, Costabel U, Glaspole I, Ogura T, Song JW, Stansen W, Quaresma M, Stowasser S, Kreuter M. Crestani B, et al. Among authors: kreuter m. Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14. Lancet Respir Med. 2019. PMID: 30224318 Clinical Trial.
The primary outcome of INPULSIS-ON was to characterise the long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis, and this was analysed in patients who received at least one dose of nintedanib in INPULSIS-ON. ...INTERPRETATION: Thes …
The primary outcome of INPULSIS-ON was to characterise the long-term safety and tolerability of nintedanib in patients with idiopathi …
The threat in chronic lung diseases: acute exacerbations.
Kreuter M, Cottin V. Kreuter M, et al. Eur Respir Rev. 2017 Sep 27;26(145):170075. doi: 10.1183/16000617.0075-2017. Print 2017 Sep 30. Eur Respir Rev. 2017. PMID: 28954770 Free PMC article.
Acute worsening of chronic lung disease is increasingly recognised as one of the main causes of disease progression, loss of health-related quality of life, and disease-associated mortality. While substantial progress has been made in the long-term management of most chron …
Acute worsening of chronic lung disease is increasingly recognised as one of the main causes of disease progression, loss of health-related …
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.
Raghu G, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Burgess T, Kamath N, Donaldson F, Richeldi L. Raghu G, et al. Among authors: kreuter m. Respir Res. 2022 May 21;23(1):129. doi: 10.1186/s12931-022-02047-0. Respir Res. 2022. PMID: 35597980 Free PMC article. Clinical Trial.
The OLE primary objective was to assess the long-term safety and tolerability of rhPTX-2. Other outcomes included FVC, 6MWD, and patient-reported outcomes (descriptive analysis). ...For patients starting vs continuing rhPTX-2, mean (95% confidence interval) changes from ba …
The OLE primary objective was to assess the long-term safety and tolerability of rhPTX-2. Other outcomes included FVC, 6MWD, and pati …
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study.
Desai SR, Sivarasan N, Johannson KA, George PM, Culver DA, Devaraj A, Lynch DA, Milne D, Renzoni E, Nunes H, Sverzellati N, Spagnolo P, Baughman RP, Yadav R, Piciucchi S, Walsh SLF, Kouranos V, Wells AU; Sarcoid Delphi Group. Desai SR, et al. Lancet Respir Med. 2024 May;12(5):409-418. doi: 10.1016/S2213-2600(23)00267-9. Epub 2023 Dec 14. Lancet Respir Med. 2024. PMID: 38104579 Review.
One view of sarcoidosis is that the term covers many different diseases. However, no classification framework exists for the future exploration of pathogenetic pathways, genetic or trigger predilections, patterns of lung function impairment, or treatment separations, or fo …
One view of sarcoidosis is that the term covers many different diseases. However, no classification framework exists for the future e …
YouTube-videos for patient education in lymphangioleiomyomatosis?
Wilkens FM, Ganter C, Kriegsmann K, Wilkens H, Kahn N, Goobie GC, Ryerson CJ, Kreuter M. Wilkens FM, et al. Among authors: kreuter m. Respir Res. 2022 Apr 27;23(1):103. doi: 10.1186/s12931-022-02022-9. Respir Res. 2022. PMID: 35477513 Free PMC article.
METHODS: The first 200 video hits on YouTube in English for the search term "lymphangioleiomyomatosis" were recorded. All videos suitable for patient education on LAM were included. ...
METHODS: The first 200 video hits on YouTube in English for the search term "lymphangioleiomyomatosis" were recorded. All videos suit …
[Addictive inhalants-A challenge for the lungs].
Bauer-Kemény C, Kreuter M. Bauer-Kemény C, et al. Among authors: kreuter m. Pneumologe (Berl). 2022;19(1):49-59. doi: 10.1007/s10405-021-00428-8. Epub 2022 Jan 4. Pneumologe (Berl). 2022. PMID: 35002591 Free PMC article. German.
Clear conclusions are also currently not possible for the long-term effects of cannabis use on the lungs and respiratory tract. ...
Clear conclusions are also currently not possible for the long-term effects of cannabis use on the lungs and respiratory tract. ...
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis.
Kreuter M, Bonella F, Blank N, Riemekasten G, Müller-Ladner U, Henes J, Siegert E, Günther C, Kötter I, Pfeiffer C, Schmalzing M, Zeidler G, Korsten P, Susok L, Juche A, Worm M, Jandova I, Ehrchen J, Sunderkötter C, Keyßer G, Ramming A, Schmeiser T, Kreuter A, Kuhr K, Lorenz HM, Moinzadeh P, Hunzelmann N. Kreuter M, et al. Rheumatology (Oxford). 2023 Sep 1;62(9):3067-3074. doi: 10.1093/rheumatology/kead023. Rheumatology (Oxford). 2023. PMID: 36708008 Free PMC article.
We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD). ...
We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated …
Supportive and palliative care of advanced nonmalignant lung disease.
Kreuter M, Herth FJ. Kreuter M, et al. Respiration. 2011;82(4):307-16. doi: 10.1159/000330730. Epub 2011 Sep 15. Respiration. 2011. PMID: 21921670 Free article. Review.
The discomfort of many physicians, caregivers, and family members with discussions about end-of-life care is one obstacle for the timely initiation of palliative care and the uncertainty of the short-term prognosis in most advanced nonmalignant respiratory diseases. ...
The discomfort of many physicians, caregivers, and family members with discussions about end-of-life care is one obstacle for the timely ini …
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.
Valenzuela C, Torrisi SE, Kahn N, Quaresma M, Stowasser S, Kreuter M. Valenzuela C, et al. Among authors: kreuter m. Respir Res. 2020 Jan 6;21(1):7. doi: 10.1186/s12931-019-1269-6. Respir Res. 2020. PMID: 31906942 Free PMC article. Review.
The use of nintedanib to treat patients with advanced lung function impairment, concomitant emphysema, patients awaiting lung transplantation and patients with IPF and lung cancer is discussed. The long-term use of nintedanib and an up-to-date summary of nintedanib in clin …
The use of nintedanib to treat patients with advanced lung function impairment, concomitant emphysema, patients awaiting lung transplantatio …
Non-small-cell lung cancer: multimodality approach in stage-III resectable disease.
Thomas M, Hoffknecht P, Droege C, Baisch A, Reinmuth N, Kreuter M, Lange T, Berdel WE. Thomas M, et al. Among authors: kreuter m. Lung Cancer. 2004 Aug;45 Suppl 2:S99-105. doi: 10.1016/j.lungcan.2004.07.985. Lung Cancer. 2004. PMID: 15552789 Review.
The long-term results of surgery +/- radiotherapy in patients with operable disease of locally advanced non-small-cell lung cancer are discouraging. In the vast majority, disseminated microscopic disease, resulting in the later occurrence of distant metastases, contributes …
The long-term results of surgery +/- radiotherapy in patients with operable disease of locally advanced non-small-cell lung cancer ar …
44 results